Hem › Schizofreni › Illinois
Kliniska studier för Schizofreni i Illinois
26 studier för Schizofreni söker deltagare vid platser i Illinois.
Städer i Illinois
Officiell studietext (engelska)
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- The University of Chicago, Chicago
RekryterarFriska volontärer välkomna
Ålder 18 till 59 · Alla kön · Uppdaterad 2 okt. 2026 · NCT07853807Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
RekryterarFas 1
Ålder 18 till 55 · Alla kön · Uppdaterad 28 sep. 2026 · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 28 sep. 2026 · NCT07686263Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
RekryterarFas 3
Ålder 5 till 17 · Alla kön · Uppdaterad 25 sep. 2026 · NCT06229210NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 25 sep. 2026 · NCT07114874A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
RekryterarFas 3
Ålder 5 till 17 · Alla kön · Uppdaterad 22 sep. 2026 · NCT07424404A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
RekryterarFas 2
Ålder 18 till 55 · Alla kön · Uppdaterad 22 sep. 2026 · NCT07410507A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
RekryterarFas 4
Ålder 18 och äldre · Alla kön · Uppdaterad 18 sep. 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 9 sep. 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
RekryterarFas 3
Ålder 13 till 17 · Alla kön · Uppdaterad 4 sep. 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
RekryterarFas 1
Ålder 18 till 55 · Alla kön · Uppdaterad 2 sep. 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
RekryterarFas 2
Ålder 18 till 65 · Alla kön · Uppdaterad 1 sep. 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 19 aug. 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
RekryterarFas 3
Ålder 10 till 17 · Alla kön · Uppdaterad 14 aug. 2026 · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
RekryterarFas 2
Ålder 18 till 65 · Alla kön · Uppdaterad 29 juli 2026 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 27 juli 2026 · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
RekryterarObservationsstudie
Ålder 18 till 40 · Alla kön · Uppdaterad 20 juli 2026 · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
RekryterarFas 2
Ålder 18 till 55 · Alla kön · Uppdaterad 23 juni 2026 · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
RekryterarFas 4
Ålder 18 till 65 · Alla kön · Uppdaterad 3 juni 2026 · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
RekryterarFas 4
Ålder 18 till 60 · Alla kön · Uppdaterad 11 maj 2026 · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
RekryterarObservationsstudie
Ålder 18 till 40 · Alla kön · Uppdaterad 10 mars 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 6 mars 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 12 jan. 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
RekryterarFas 2
Ålder 21 till 55 · Alla kön · Uppdaterad 26 dec. 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
RekryterarFas 3Friska volontärer välkomna
Ålder 18 till 65 · Alla kön · Uppdaterad 19 dec. 2024 · NCT05184335Från ClinicalTrials.gov, data hämtad 3 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.